Skip to main content

Advertisement

SpringerLink
Log in

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007.

Methods

S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9).

Results

S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%).

Conclusion

The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53.

    Article  PubMed  CAS  Google Scholar 

  2. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature (London). 1989;342(6250):705–8.

    Article  CAS  Google Scholar 

  3. Kawakami M, Yamaguchi T, Takahashi K, Matsumoto H, Yasutome M, Horiguchi S, et al. Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer. Surg Today. 2010;40(3):245–50.

    Article  PubMed  CAS  Google Scholar 

  4. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol. 1995;147(3):790–8.

    PubMed  CAS  Google Scholar 

  5. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335(8691):675–9.

    Article  PubMed  CAS  Google Scholar 

  6. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res. 1996;56(21):4917–21.

    Google Scholar 

  7. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266(5186):807–10.

    Article  PubMed  CAS  Google Scholar 

  8. Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999;81(5):712–8.

    Article  PubMed  CAS  Google Scholar 

  9. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer. 2000;85(6):791–5.

    Article  PubMed  CAS  Google Scholar 

  10. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 1995;72(3):637–41.

    Article  PubMed  CAS  Google Scholar 

  11. Takeda A, Nakajima K, Shimada H, Imaseki H, Takayama W, Hayashi H, et al. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J Surg Oncol. 1999;71(2):112–6.

    Article  PubMed  CAS  Google Scholar 

  12. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, et al. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000;45(1):122–8.

    Article  PubMed  CAS  Google Scholar 

  13. Broll R, Duchrow M, Oevermann E, Wellm C, Schwandner O, Schimmelpenning H, et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis. 2001;16(1):22–7.

    Article  PubMed  CAS  Google Scholar 

  14. Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, et al. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur J Surg. 2001;167(1):50–3.

    Article  PubMed  CAS  Google Scholar 

  15. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19(2):114–20.

    Article  PubMed  Google Scholar 

  16. Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33(2):272–7.

    Article  PubMed  Google Scholar 

  17. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Cancer (Philadelphia). 2000;89(8):1677–83.

    Article  CAS  Google Scholar 

  18. Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T, et al. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol. 2001;6(1):45–9.

    Article  PubMed  CAS  Google Scholar 

  19. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer (Philadelphia). 2003;97(3):682–9.

    Article  Google Scholar 

  20. Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16(9):2516–23.

    Article  PubMed  Google Scholar 

  21. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer. 2001;94(6):859–63.

    Article  PubMed  CAS  Google Scholar 

  22. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (Philadelphia). 1999;85(2):302–8.

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, National Tokyo Medical Center, Tokyo, Japan

    Hiroki Ochiai, Takashi Ohishi, Koji Osumi, Jo Tokuyama, Hidejirou Urakami, Shikou Seki, Atsushi Shimada, Akira Matsui, Yoh Isobe & Sumio Matsumoto

  2. Department of Pathology, National Tokyo Medical Center, Tokyo, Japan

    Yuya Murata

  3. Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan

    Hiroki Ochiai, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa & Yuko Kitagawa

Authors
  1. Hiroki Ochiai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Ohishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Osumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jo Tokuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hidejirou Urakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shikou Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoh Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuya Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takashi Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshiyuki Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hirotoshi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sumio Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yuko Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Ochiai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ochiai, H., Ohishi, T., Osumi, K. et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 42, 164–168 (2012). https://doi.org/10.1007/s00595-011-0044-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-011-0044-1

Keywords

Search

Navigation